Pages
Products
AAV9-CAG-FLPo

AAV9-CAG-FLPo

Cat.No. :  AAV00267Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00267Z
Description AAV serotype 9 particles contain FLPo recombinase under CAG promoter.
Serotype AAV Serotype 9
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

In the dynamic landscape of gene therapy, adeno-associated virus (AAV) has emerged as an important delivery vector, showing great potential for treating various genetic diseases. In recent years, the field has made great progress, and several AAV-based products have been approved. These products highlight the success and increasing acceptance of viral vectors as safe and effective delivery vehicles for therapeutic and vaccine genes in the clinic. AAV has a genome of approximately 4.7 kb, containing two major open reading frames (ORFs), rep and cap, flanked by two inverted terminal repeats (ITRs). The alternative reading frame present in the cap contains aap and maap. The cap ORF also encodes three overlapping capsid viral proteins (VP) in mRNA generated by alternative splicing. The larger transcript contains the entire cap coding region and produces VP1, while the shorter transcript encodes VP2 (ACG) and VP3 (AUG) from two separate start codons. Thus, the VP1 (87 kDa) and VP2 (72 kDa) capsid proteins have the same ∼530 C-terminal amino acid sequence within VP3, but have additional amino acids at the N terminus. A total of 60 VPs assemble into a T=1 icosahedral viral capsid with a 1:1:10 ratio of VP1, VP2, and VP3, respectively, with VP3 accounting for ∼90% of the capsid.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Invaluable tool

AAV9-CAG-FLPo's ability to cross the blood-brain barrier and deliver payloads effectively has brought a new depth to our gene therapy experiments.

Germany

01/06/2021

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction